A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder
June 17 (Reuters) – Bristol-Myers Squibb Co (BMY.N) and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug.
Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said.
They would jointly develop and market the drug, MORAb-202, in Asia, Europe, the United States and Canada.
Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc (AGEN.O) to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell lung cancer.
The drugmaker has been betting on sales of its Opdivo drug to treat such cancers, in a market currently dominated by Merck & Co’s (MRK.N) rival treatment, Keytruda.
Eisai’s drug, MORAb-202, is being developed for the treatment of solid tumors, including ovarian, lung and breast cancers and is in the early stage of development.
Bristol-Myers will pay Eisai a royalty on sales outside of the collaboration territories, the companies said.Reporting by Amruta Khandekar; Editing by Vinay Dwivedi
Our Standards: The Thomson Reuters Trust Principles.
FIA President Mohammed Ben Sulayem hails new agreement as a vital step forward for racing…
Indonesia’s rapidly expanding investor community is creating a new opportunity for financial technology companies: connecting…
Nevada’s emergence as a life sciences destination is gaining momentum, and Roseman Bioventures is positioning…
Hyperion Materials & Technologies is working with CADDi to centralise engineering data and accelerate quotation…
Launching a business in Ontario is an exciting but strategic endeavour that begins with a…
The next stage of premium consumer electronics is increasingly about ecosystems rather than individual devices.…